Covered recipient · General Payments record
KEMKA S OGBURIA
Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery
General Payments · PY2018–2024
$1,807.44
- Reported across 43 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $471.29 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $120.53 | 1 |
| ABBVIE INC. | $107.36 | 4 |
| LEO Pharma Inc. | $46.98 | 2 |
| GENZYME CORPORATION | $46.82 | 2 |
| Lilly USA, LLC | $39.20 | 2 |
| Amgen Inc. | $37.93 | 2 |
| Smith & Nephew, Inc. | $36.85 | 1 |
| Janssen Biotech, Inc. | $19.91 | 1 |
| Verrica Pharmaceuticals Inc. | $15.71 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $23.78 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105147096 | CMS |
| ABBVIE INC. | $17.13 | 08/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105147098 | CMS |
| ABBVIE INC. | $34.68 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105147100 | CMS |
| ABBVIE INC. | $31.77 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105147102 | CMS |
| Amgen Inc. | $14.77 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117342406 | CMS |
| Amgen Inc. | $23.16 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117342408 | CMS |
| GENZYME CORPORATION | $27.34 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139994529 | CMS |
| GENZYME CORPORATION | $19.48 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139994533 | CMS |
| Gilead Sciences, Inc. | $120.53 | 01/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133736976 | CMS |
| Janssen Biotech, Inc. | $19.91 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078437865 | CMS |
| LEO Pharma Inc. | $22.83 | 01/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152644923 | CMS |
| LEO Pharma Inc. | $24.15 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152644925 | CMS |
| Lilly USA, LLC | $20.70 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135125690 | CMS |
| Lilly USA, LLC | $18.50 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135105475 | CMS |
| Smith+Nephew, Inc. | $36.85 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149479260 | CMS |
| Verrica Pharmaceuticals Inc. | $15.71 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118384806 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.